Our take on Shawn Ryan Show guest,
Louisa Nicola's comments about peptides.

A viral podcast clip from a recent episode of the Shawn Ryan Show features neurophysiologist Louisa Nicola declaring, plainly and with authority, that she "hates peptides" — that there has never been "not one randomized controlled trial" on peptides, that BPC-157 "failed its trial" and was cut by the FDA for being "too dangerous," and that anyone using these compounds is essentially injecting unknowns into their body without a shred of scientific backing.

The problem isn't that she raised concerns. Concerns about gray-market sourcing, lack of large-scale Phase 3 trials for specific compounds, and unregulated use are legitimate and worth discussing. The problem is the delivery: sweeping factual errors, stated with authority, to an audience of millions, by someone with a clinical credential. That combination is not a safety warning. It is a misinformation event — and it carries consequences that reach far beyond any single podcast.

This is demonstrably false. Peptides are one of the most studied classes of therapeutic agents in modern pharmacology. The blanket claim that no RCTs exist collapses entirely the moment you look at the published literature or the FDA's own approval record. She carves out GLP-1s and insulin — but even excluding those, the list of peptide drugs that have completed Phase 3 RCTs and received FDA approval is extensive.

This is not what happened. BPC-157 has not failed a completed FDA clinical trial. There was no Phase 3 trial halted due to dangerous adverse events or deaths. There is no FDA press release, no MedWatch safety alert, and no clinical hold notice on record matching this description of BPC-157 specifically.

What actually happened is regulatory in nature — not clinical. In 2023, the FDA added BPC-157 to its Category 2 list under 503A and 503B compounding regulations. This designation means BPC-157 cannot be used as a bulk substance in compounded preparations. The stated basis was insufficient clinical evidence to justify compounding exemptions — not a finding that it caused deaths or serious harm in a completed trial.

This is the most intellectually dishonest framing in the segment — not because the question is wrong to ask, but because it is presented as a near-certain outcome rather than an unresolved theoretical concern. The actual preclinical literature on BPC-157 and cancer is genuinely mixed, and several studies point in the opposite direction from what she implies.

BPC-157 does stimulate angiogenesis — that part is accurate. But the mechanism is primarily mediated through the NO-system and upregulation of VEGF in the context of wound healing, not systemic indiscriminate vascular growth. Multiple animal studies have observed anti-inflammatory and anti-tumor adjacent effects, suggesting the full picture is considerably more complex than 'it feeds cancer.'

What makes this segment more damaging than a random internet post is the source. Louisa Nicola is not a fringe voice. She is a credentialed neurophysiologist with a large, educated, health-conscious audience. When she says 'I hate peptides' with a clinical credential attached, the audience does not hear an opinion. They hear a clinical verdict. That's the power — and the responsibility — of platform.

The most revealing moment in the segment comes when Nicola says: 'If you could go to the doctor and get cleared... and they've passed clinical trials and they're safe, then yeah, take your BPC-157.' That conditional is the entire point. The path to that future is more research, more clinical engagement, more physicians willing to have informed conversations with patients — not fewer. Every public declaration that peptides are categorically dangerous makes that future harder to reach.

The logic of 'don't use this until it's been properly studied, and also dismiss it publicly so it's harder to study' is a closed loop that serves no one. Meanwhile, a combat veteran with a destroyed shoulder, or a woman with a GI condition that conventional medicine hasn't touched, goes online and finds BPC-157 on a gray market vendor site with no guidance, no physician involvement, and no safety monitoring. That outcome is not the result of too much openness about peptides. It is the result of too little.

“When credentialed voices close the door on legitimate inquiry, patients don't stop looking. They just stop looking in safe places.”

Somewhere in the audience for that episode was a person with a chronic injury who has exhausted conventional options. There was a veteran dealing with tendon damage that hasn't responded to anything his VA has offered. There was someone with a leaky gut, with treatment-resistant inflammation, with a healing timeline that has stretched into years. They heard a neurophysiologist tell them the thing they were considering is dangerous, unproven, and not worth discussing with a doctor. Some of them believed her.

The work of Peptide Initiative exists because these people deserve accurate information. Not hype. Not denial. Accurate. The peptide research landscape is genuinely early-stage in several key areas, genuinely promising in others, and genuinely complex in its regulatory status. It requires nuance. It requires precision. What it does not require is a credentialed voice declaring 'I hate peptides' and letting the echo chamber fill in the rest.

The path to a world where BPC-157 has a completed Phase 3 RCT, where physicians can have informed evidence-backed conversations about secretagogues, where gray-market sourcing is obsolete because legitimate clinical access exists — that path runs directly through the kind of rigorous, honest, evidence-grounded public discourse that sweeping dismissal destroys. Every time a credentialed voice says 'I hate peptides' instead of 'here is what we know and what we don't,' that path gets longer.